From: Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
 | Recurrence | No recurrence | p value | ||
---|---|---|---|---|---|
n | 9 | Â | 187 | Â | Â |
Mean age (SD) | 55.3 | (13.9) | 55.9 | (12.1) | n.s. |
Stagea | Â | Â | Â | Â | Â |
   I | 2 |  | 87 |  |  |
  IIA or B | 4 |  | 96 |  | <0.01 |
  IIIA or B | 3 |  | 4 |  |  |
Histology | Â | Â | Â | Â | Â |
  Ductal | 7 |  | 161 |  |  |
  Lobular | 2 |  | 11 |  | n.s. |
  Others | 0 |  | 15 |  |  |
High nuclear grade | 11% | (1/9) | 4% | (7/181) | n.s. |
High histological grade | 22% | (2/9) | 4% | (6/141) | n.s. |
ERb | 100% | (9/9) | 100% | (187/187) | n.s. |
PRb | 67% | (6/9) | 78% | (145/187) | n.s. |
Mean Ki67 (%) (SD) | 37.9 | (21.7) | 24.1 | (18.5) | <0.05 |
(Neo-) adjuvant therapy | Â | Â | Â | Â | Â |
  Endocrine + chemotherapy | 9 |  | 52 |  |  |
  Endocrine therapy only | 0 |  | 127 |  |  |
  Chemotherapy only | 0 |  | 1 |  |  |
  None | 0 |  | 7 |  |  |